JNJ 17299425

Drug Profile

JNJ 17299425

Alternative Names: JNJ-17299425

Latest Information Update: 02 Apr 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johnson & Johnson
  • Class Neuropsychotherapeutics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Brain injuries

Most Recent Events

  • 01 Aug 2008 Discontinued - Phase-II for Brain injuries in Belgium (IV)
  • 01 Aug 2008 Discontinued - Phase-II for Brain injuries in France (IV)
  • 01 Aug 2008 Johnson & Johnson terminates phase II trial in Brain injuries in Belgium & France due to reprioritisation of company activities (NCT01814982)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top